Office of the Commissioner of Lobbying of Canada Office of the Commissioner of Lobbying of Canada

Language selection

Registry of Lobbyists

Advanced Registry Search Results

Search History (1)

Search Criteria

  1. DPOH name: CLARK, DOUG
Share this search Create an alert
Start over
Modify criteria

Refine registrations results by

If you would like to view a summary of the last 12 months for a lobbying activity, use the 12-Month Lobbying Activity Search

Monthly communication reports (64)
Results: 1-50 | Export
  1. RAREi - The Canadian Forum for Rare Disease Innovators / iRARE, le Forum canadien des innovateurs spécialisés dans les maladies rares
    Type: Consultant
    Lobbyist: WILLIAM DEMPSTER, 3Sixty Public Affairs Inc.
    Occurred: 2022-12-05
    Posted: 2023-01-16
    Designated public office holders:
    • Douglas Clark, Executive Director | Patented Medicine Prices Review Board (PMPRB)
    Subject matters:
    • Intellectual Property
    • International Trade
    • Industry
    • Economic Development
    • Health
    • Taxation and Finance
    • Science and Technology
      •
  2. RAREi - The Canadian Forum for Rare Disease Innovators / iRARE, le Forum canadien des innovateurs spécialisés dans les maladies rares
    Type: Consultant
    Lobbyist: GERALD JEFFCOTT, 3Sixty Public Affairs
    Occurred: 2022-12-05
    Posted: 2022-12-09
    Designated public office holders:
    • Douglas Clark, Executive Director | Patented Medicine Prices Review Board (PMPRB)
    Subject matters:
    • Health
      •
  3. Hoffmann-La Roche Limited
    Type: In-house Corporation
    Occurred: 2022-11-29
    Posted: 2022-12-13
    Designated public office holders:
    • Douglas Clark, Executive Director | Patented Medicine Prices Review Board (PMPRB)
    Subject matters:
    • Health
      •
  4. Eli Lilly Canada Inc.
    Type: In-house Corporation
    Occurred: 2022-10-27
    Posted: 2022-11-15
    Designated public office holders:
    • Douglas Clark, Executive Director | Patented Medicine Prices Review Board (PMPRB)
    Subject matters:
    • Health
      •
  5. Sun Life Financial Inc. / Financière Sun Life
    Type: In-house Corporation
    Occurred: 2022-10-19
    Posted: 2022-11-14
    Designated public office holders:
    • Douglas Clark, Executive Director | Patented Medicine Prices Review Board (PMPRB)
    Subject matters:
    • Health
      •
  6. Sun Life Financial Inc. / Financière Sun Life
    Type: In-house Corporation
    Occurred: 2022-06-10
    Posted: 2022-07-11
    Designated public office holders:
    • Douglas Clark , Executive Director | Patented Medicine Prices Review Board (PMPRB)
    Subject matters:
    • Health
      •
  7. The Canada Life Assurance Company / de la Compagnie d'Assurance du Canada sur la Vie
    Type: In-house Corporation
    Occurred: 2022-06-07
    Posted: 2022-07-15
    Designated public office holders:
    • Douglas Clark, Executive Director | Patented Medicine Prices Review Board (PMPRB)
    Subject matters:
    • Health
      •
  8. GlaxoSmithKline Inc.
    Type: In-house Corporation
    Occurred: 2022-06-01
    Posted: 2022-06-30
    Designated public office holders:
    • Douglas Clark , Executive Director | Patented Medicine Prices Review Board (PMPRB)
    Subject matters:
    • Health
      •
  9. Eli Lilly Canada Inc.
    Type: In-house Corporation
    Occurred: 2022-05-24
    Posted: 2022-06-15
    Designated public office holders:
    • Douglas Clark, Executive Director | Patented Medicine Prices Review Board (PMPRB)
    Subject matters:
    • Health
      •
  10. AbbVie Corporation
    Type: In-house Corporation
    Occurred: 2022-04-14
    Posted: 2022-04-29
    Designated public office holders:
    • Douglas Clark, Executive Director | Patented Medicine Prices Review Board (PMPRB)
    Subject matters:
    • Industry
      •
  11. Eli Lilly Canada Inc.
    Type: In-house Corporation
    Occurred: 2022-04-07
    Posted: 2022-05-16
    Designated public office holders:
    • Douglas Clark, Executive Director | Patented Medicine Prices Review Board (PMPRB)
    Subject matters:
    • Health
      •
  12. Takeda Canada Inc.
    Type: Consultant
    Lobbyist: Ian Chesney, Santis Health
    Occurred: 2020-12-14
    Posted: 2020-12-14
    Designated public office holders:
    • Doug Clark, Executive Director | Patented Medicine Prices Review Board (PMPRB)
    Subject matters:
    • Health
    • Economic Development
    • Research and Development
    • Science and Technology
      •
  13. Sunovion Pharmaceuticals Canada Inc.
    Type: Consultant
    Lobbyist: Kate Dalgleish, Compass Rose Group
    Occurred: 2020-12-09
    Posted: 2021-01-15
    Designated public office holders:
    • Elena Lungu, Manager, Policy Development | Patented Medicine Prices Review Board (PMPRB)
    • Isabel Jaen Raasch, General Counsel | Patented Medicine Prices Review Board (PMPRB)
    • Tanya Potashnik, Director, Policy & Economic Analysis Branch | Patented Medicine Prices Review Board (PMPRB)
    • Douglas Clark, Executive Director | Patented Medicine Prices Review Board (PMPRB)
    Subject matters:
    • Research and Development
    • Health
      •
  14. Eli Lilly Canada Inc.
    Type: In-house Corporation
    Occurred: 2020-10-22
    Posted: 2020-11-16
    Designated public office holders:
    • Douglas Clark, Executive Director | Patented Medicine Prices Review Board (PMPRB)
    Subject matters:
    • Health
      •
  15. Eli Lilly Canada Inc.
    Type: In-house Corporation
    Occurred: 2020-10-07
    Posted: 2020-11-16
    Designated public office holders:
    • Douglas Clark, Executive Director | Patented Medicine Prices Review Board (PMPRB)
    Subject matters:
    • Health
      •
  16. Cystic Fibrosis Canada / Fibrose kystique Canada
    Type: In-house Organization
    Occurred: 2020-08-21
    Posted: 2020-09-08
    Designated public office holders:
    • Ajaykumar Thaker, Manager, Health Products and Food Branch | Health Canada (HC)
    • Co Pham, Associate Director, Office of Clinical Trials | Health Canada (HC)
    • Carole Legare, Director, Office of Clinical Trials | Health Canada (HC)
    • Doug Clark, Executive Director, PMPRB | Health Canada (HC)
    Subject matters:
    • Health
      •
  17. Vertex Pharmaceuticals (Canada) Incorporated
    Type: In-house Corporation
    Occurred: 2020-08-12
    Posted: 2020-09-09
    Designated public office holders:
    • Douglas Clark, Executive Director | Patented Medicine Prices Review Board (PMPRB)
    Subject matters:
    • Intellectual Property
    • Health
      •
  18. Eli Lilly Canada Inc.
    Type: In-house Corporation
    Occurred: 2020-06-05
    Posted: 2020-07-14
    Designated public office holders:
    • Doug Clark, Executive Director, PMPRB | Patented Medicine Prices Review Board (PMPRB)
    Subject matters:
    • Health
      •
  19. Eli Lilly Canada Inc.
    Type: In-house Corporation
    Occurred: 2020-05-15
    Posted: 2020-06-15
    Designated public office holders:
    • Douglas Clark, Executive Director | Patented Medicine Prices Review Board (PMPRB)
    Subject matters:
    • Research and Development
    • Health
      •
  20. Cystic Fibrosis Canada / Fibrose kystique Canada
    Type: In-house Organization
    Occurred: 2020-05-04
    Posted: 2020-06-15
    Designated public office holders:
    • Douglas Clark, Executive Director | Health Canada (HC)
    Subject matters:
    • Health
      •
  21. Cystic Fibrosis Canada / Fibrose kystique Canada
    Type: In-house Organization
    Occurred: 2020-03-09
    Posted: 2020-03-15
    Designated public office holders:
    • Douglas Clark, Executive Director, Patented Medicine Prices Review Board | Health Canada (HC)
    Subject matters:
    • Health
      •
  22. Diabetes Canada / Diabète Canada
    Type: In-house Organization
    Occurred: 2020-01-22
    Posted: 2020-02-15
    Designated public office holders:
    • Douglas Clark, Executive Director | Patented Medicine Prices Review Board (PMPRB)
    Subject matters:
    • Health
      •
  23. CANADIAN CANCER SOCIETY / Société canadienne du cancer
    Type: In-house Organization
    Occurred: 2019-12-10
    Posted: 2020-01-15
    Designated public office holders:
    • Douglas Clark, Executive Director, Exective Director's office | Patented Medicine Prices Review Board (PMPRB)
    Subject matters:
    • Health
      •
  24. Takeda Canada Inc.
    Type: Consultant
    Lobbyist: Ian Chesney, Santis Health
    Occurred: 2019-07-29
    Posted: 2019-07-29
    Designated public office holders:
    • Douglas Clark, Executive Director | Patented Medicine Prices Review Board (PMPRB)
    Subject matters:
    • Science and Technology
    • Research and Development
    • Budget
    • Economic Development
    • Health
      •
  25. Eli Lilly Canada Inc.
    Type: In-house Corporation
    Occurred: 2019-05-29
    Posted: 2019-06-11
    Designated public office holders:
    • Douglas Clark, Executive Director | Patented Medicine Prices Review Board (PMPRB)
    Subject matters:
    • Health
    • Industry
      •
  26. Eli Lilly Canada Inc.
    Type: In-house Corporation
    Occurred: 2019-03-07
    Posted: 2019-03-18
    Designated public office holders:
    • Douglas Clark, Executive Director, PMPRB | Patented Medicine Prices Review Board (PMPRB)
    Subject matters:
    • Health
    • Research and Development
    • Industry
      •
  27. Novo Nordisk Canada Inc.
    Type: In-house Organization
    Occurred: 2018-12-11
    Posted: 2018-12-17
    Designated public office holders:
    • Doug Clark, Executive Director | Patented Medicine Prices Review Board (PMPRB)
    • Tanya Potashnick, Director | Patented Medicine Prices Review Board (PMPRB)
    • Matthew Kellison, Director | Patented Medicine Prices Review Board (PMPRB)
    Subject matters:
    • Health
    • Industry
      •
  28. Eli Lilly Canada Inc.
    Type: In-house Corporation
    Occurred: 2018-12-04
    Posted: 2019-01-13
    Designated public office holders:
    • Douglas Clark, Executive Director | Patented Medicine Prices Review Board (PMPRB)
    Subject matters:
    • Health
    • Economic Development
      •
  29. Eli Lilly Canada Inc.
    Type: In-house Corporation
    Occurred: 2018-10-25
    Posted: 2018-11-01
    Designated public office holders:
    • Douglas Clark, Executive Director | Patented Medicine Prices Review Board (PMPRB)
    Subject matters:
    • Health
    • Industry
      •
  30. Eli Lilly Canada Inc.
    Type: In-house Corporation
    Occurred: 2018-09-11
    Posted: 2018-09-28
    Designated public office holders:
    • Douglas Clark, Executive Director | Patented Medicine Prices Review Board (PMPRB)
    Subject matters:
    • Health
    • Industry
      •
  31. Eli Lilly Canada Inc.
    Type: In-house Corporation
    Occurred: 2018-07-17
    Posted: 2018-08-13
    Designated public office holders:
    • Douglas Clark, Executive Director, PMPRB | Health Canada (HC)
    Subject matters:
    • Health
      •
  32. GlaxoSmithKline Inc.
    Type: In-house Corporation
    Occurred: 2018-06-28
    Posted: 2018-07-05
    Designated public office holders:
    • Doug Clark, Executive Director, PMPRB | Patented Medicine Prices Review Board (PMPRB)
    Subject matters:
    • Science and Technology
    • Health
    • Research and Development
    • Economic Development
      •
  33. Eli Lilly Canada Inc.
    Type: In-house Corporation
    Occurred: 2018-06-27
    Posted: 2018-08-13
    Designated public office holders:
    • Douglas Clark, Executive Director, PMPRB | Health Canada (HC)
    Subject matters:
    • Health
      •
  34. Eli Lilly Canada Inc.
    Type: In-house Corporation
    Occurred: 2018-05-17
    Posted: 2018-08-13
    Designated public office holders:
    • Douglas Clark, Executive Director, Patented Medicines Review Board | Health Canada (HC)
    Subject matters:
    • Economic Development
    • Health
    • Industry
      •
  35. Novo Nordisk Canada Inc.
    Type: In-house Organization
    Occurred: 2018-05-08
    Posted: 2018-09-07
    Designated public office holders:
    • Douglas Clark, Executive Director, PMPRB | Patented Medicine Prices Review Board (PMPRB)
    Subject matters:
    • Health
    • Economic Development
    • Research and Development
    • Intellectual Property
      •
  36. Eli Lilly Canada Inc.
    Type: In-house Corporation
    Occurred: 2018-04-10
    Posted: 2018-04-12
    Designated public office holders:
    • Douglas Clark, Executive Director | Patented Medicine Prices Review Board (PMPRB)
    Subject matters:
    • Health
    • Industry
      •
  37. BIOTECANADA
    Type: In-house Organization
    Occurred: 2018-04-09
    Posted: 2018-05-23
    Designated public office holders:
    • Douglas Clark, Executive Director | Patented Medicine Prices Review Board (PMPRB)
    Subject matters:
    • Health
      •
  38. Eli Lilly Canada Inc.
    Type: In-house Corporation
    Occurred: 2018-03-07
    Posted: 2018-03-16
    Designated public office holders:
    • Douglas Clark, Executive Director | Patented Medicine Prices Review Board (PMPRB)
    Subject matters:
    • Health
      •
  39. Eli Lilly Canada Inc.
    Type: In-house Corporation
    Occurred: 2017-10-10
    Posted: 2017-10-23
    Designated public office holders:
    • Douglas Clark, Executive Director | Patented Medicine Prices Review Board (PMPRB)
    Subject matters:
    • Health
    • Industry
      •
  40. Eli Lilly Canada Inc.
    Type: In-house Corporation
    Occurred: 2017-08-03
    Posted: 2017-09-05
    Designated public office holders:
    • douglas clark, Executive Director, Patented Medicines Pricing Review Board | Health Canada (HC)
    Subject matters:
    • Economic Development
    • Industry
    • Health
      •
  41. Hoffmann-La Roche Limited
    Type: In-house Corporation
    Occurred: 2017-07-26
    Posted: 2017-08-10
    Designated public office holders:
    • Douglas Clark, Executive Director, Patented Medicines Prices Review Board | Patented Medicine Prices Review Board (PMPRB)
    Subject matters:
    • Health
      •
  42. Eli Lilly Canada Inc.
    Type: In-house Corporation
    Occurred: 2017-05-23
    Posted: 2017-05-23
    Designated public office holders:
    • Douglas Clark, Executive Director | Patented Medicine Prices Review Board (PMPRB)
    Subject matters:
    • Economic Development
    • Research and Development
    • Industry
    • Intellectual Property
    • Health
    • International Trade
      •
  43. Bausch Health, Canada Inc. / Bausch Health, Canada Inc. Solutions de Sante
    Type: In-house Organization
    Occurred: 2017-03-23
    Posted: 2017-06-01
    Designated public office holders:
    • Ted Falk, Member of Parliment | House of Commons
    • Douglas Clark, Executive Director, PMPRB | Health Canada (HC)
    Subject matters:
    • Health
    • Industry
      •
  44. Amgen Canada Inc.
    Type: In-house Corporation
    Occurred: 2017-02-13
    Posted: 2017-03-15
    Designated public office holders:
    • Douglas Clark, Director General | Patented Medicine Prices Review Board (PMPRB)
    Subject matters:
    • Intellectual Property
    • Health
      •
  45. Bausch Health, Canada Inc. / Bausch Health, Canada Inc. Solutions de Sante
    Type: In-house Organization
    Occurred: 2016-11-22
    Posted: 2016-11-24
    Designated public office holders:
    • Douglas Clark, Executive Director | Patented Medicine Prices Review Board (PMPRB)
    Subject matters:
    • Health
      •
  46. Canadian Generic Pharmaceutical Association (CGPA) / L'Association canadienne du médicament générique (ACMG)
    Type: In-house Organization
    Occurred: 2016-10-12
    Posted: 2016-11-15
    Designated public office holders:
    • Doug Clark, Executive Director | Patented Medicine Prices Review Board (PMPRB)
    Subject matters:
    • Industry
    • Intellectual Property
      •
  47. Apotex Inc.
    Type: In-house Corporation
    Occurred: 2016-10-12
    Posted: 2016-11-21
    Designated public office holders:
    • Doug Clark, Executive Director | Patented Medicine Prices Review Board (PMPRB)
    Subject matters:
    • Industry
    • Intellectual Property
      •
  48. Teva Canada Limited / Teva Canada Limitee
    Type: In-house Corporation
    Occurred: 2016-10-12
    Posted: 2016-11-15
    Designated public office holders:
    • Douglas Clark, Executive Director | Patented Medicine Prices Review Board (PMPRB)
    Subject matters:
    • Industry
    • Intellectual Property
      •
  49. Eli Lilly Canada Inc.
    Type: In-house Corporation
    Occurred: 2016-10-11
    Posted: 2016-11-14
    Designated public office holders:
    • Douglas Clark, Executive Director | Patented Medicine Prices Review Board (PMPRB)
    Subject matters:
    • Economic Development
    • Health
    • Intellectual Property
    • Industry
    • Research and Development
      •
  50. GlaxoSmithKline Inc.
    Type: In-house Corporation
    Occurred: 2016-07-14
    Posted: 2016-08-15
    Designated public office holders:
    • Douglas Clark, Executive Director | Patented Medicine Prices Review Board (PMPRB)
    Subject matters:
    • Health
    • Intellectual Property
    • Consumer Issues
    • Research and Development
      •
Date Modified: